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The molecular mechanisms and candidate genes involved in development of 
meningiomas still need investigation and elucidation. 
In the present study thirty-three meningiomas were analyzed regarding genetic changes of 
tumor suppressor gene Adenomatous polyposis coli (APC), a component of the wnt signaling. 
Gene instability was tested by polymerase chain reaction/loss of heterozygosity (LOH) using 
Restriction Fragment Length Polymorphism (RFLP) method. RFLP was performed by two 
genetic markers, Rsa I in APC’s exon 11 and Msp I in its exon 15. The results of our analysis 
showed altogether 15 samples with LOH of the APC gene out of 32 heterozygous patients 
(47%). Seven patients had LOHs at both exons, while 4 LOHs were exclusive for exon 11 and 
4 for exon 15. The changes were distributed according to pathohistological grade as follows: 
46% of meningothelial meningioma showed LOH; 33% of fibrous; 75% of mixed 
(transitional); 75% of angiomatous, and one LOH was found in a single case of 
psammomatous meningioma. None of the LOHs were found in atypical and anaplastic cases. 
Immunostaining showed that samples with LOHs were accompanied with the absence of APC 
protein expression or presence of mutant APC proteins (χ2 =13.81, df = 2, P<0.001). We also 
showed that nuclear localization of beta-catenin correlates to APC genetic changes (χ2 =21,96, 
df = 2, P<0.0001). 
The results of this investigation suggest that genetic changes of APC gene play a role 
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We investigated loss of heterozygosity of the adenomatous polyposis coli (APC) gene 
in human central nervous system (CNS) tumors - meningiomas. The gene (chromosome 5q21) 
is organized in 16 translated exons and encodes a 2843 amino acid protein that is expressed in 
specific (frequently post-replicative) epithelial and mesenchymal cells of a number of fetal 
and adult human tissues [1]. The protein product of this tumor suppressor gene plays a role as 
a component of the wnt signal transduction pathway [2]. It has been well documented that wnt 
genes and other components of wnt signaling, are implicated in tumorigenesis [3, 4] and lately 
also in brain tumorigenesis [5-7]. APC acts as a negative regulator of the wnt signaling, being 
a critical component of the beta-catenin destruction machinery heading to the proteasome. In 
response to wnt signaling, or under the circumstances of mutated APC, beta-catenin is 
stabilized, accumulates in the cytoplasm and enters the nucleus, where it finds a partner, a 
member of the DNA binding protein family LEF/TCF. Together they activate new gene 
expression programs, among others, c-myc and cyclin D1 [8].  
Meningiomas account for approximately 20% of primary intracranial and intraspinal 
neoplasms originating from the meningeal coverings of the brain and the spinal cord. The 
majority of meningiomas corresponds to grade I of WHO classification of CNS tumors and 
thus are benign, slowly growing tumors [9, 10]. Nevertheless, there are also those who will 
exhibit features of malignant behavior. The majority of meningiomas suffer losses on 22q 
including loss of heterozygosity of the neurofibromatosis type 2 gene (NF2). Up to 60% of 
meningiomas carry inactivating mutations in the remaining NF2 allele. Loss of expression of 
NF2 protein product merlin is consistent finding in all NF2 associated meningiomas and in 
about half of sporadic benign cases [11]. Relevant genetic alterations of atypical and 
anaplastic meningiomas are still unknown. Although several molecular studies have examined 
alterations of other tumor suppressor genes and oncogenes in meningiomas [12], the etiology 
and pathogenesis of this neoplasm still need to be elucidated.  
There are several reasons why we propose studying APC in meningiomas. New 
knowledge on wnt signaling shows that wnt proteins and other components of the wnt 
signaling cascade, like beta-catenin and axin regulate critical developmental processes of 
normal CNS development [13-16]. Although APC has been thought of primarily as a colon-
specific tumor suppressor gene, its high expression in the CNS [17] and its critical 
involvement in particular syndromes, like the Tourcot syndrome [18], which includes the 
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development of primary brain tumors such as medulloblastomas and gliomas [19], suggests 
that it performs important functions in these tissues also. 
Materials and methods  
Tumor specimen  
Samples of 33 meningiomas together with 33 autologous blood tissues were collected 
from the Department of Neurosurgery, University Hospital “Sisters of Charity”, Zagreb, 
Croatia. Using the magnetic resonance imaging (MRI) tumor lesions were found in different 
cerebral regions, with the surrounding zone of perifocal oedema. During the operative 
procedure the tumor was maximally reduced using a microneurosurgical technique. The 
patients had no family history of brain tumors and did not undergo chemotherapy or 
radiotherapy prior to surgery. Collected tumor tissues were frozen in liquid nitrogen and 
transported to the laboratory, where they were immediately transferred at -75°C. The 
peripheral blood samples were collected in EDTA and processed immediately. All tumors 
were studied by pathologists and classified according to the WHO criteria [9]. There were 14 
meningothelial meningiomas, 6 fibrous (fibroblastic), 4 transitional (mixed), 1 
psammomatous, 4 angiomatous, 2 atypical and 2 anaplastic. 
Seventeen patients were female, and sixteen male. The age of patients varied from 35 
to 76 (mean age=60.4 years). The mean age at diagnosis for females was 63, and for males 58 
years. 
The local Ethical Committee approved our study and patients gave their informed 
consent. 
DNA extraction.  
 Approximately 0.5 g of tumor tissue was homogenized with 1 ml extraction buffer (10 
mM Tris HCl, pH 8.0; 0.1 M EDTA, pH 8.0; 0.5% sodium dodecyl sulfate) and incubated 
with proteinase K (100 µg/ml; Sigma, USA; overnight at 37°C). Phenol chloroform extraction 
and ethanol precipitation followed.  
 Blood was used to extract leucocyte DNA. Five ml of blood was lysed with 7 ml 
distilled water and centrifuged (15 min/5000 g). The pellet was then processed as for DNA 
extraction from the tissue samples. 
Polymerase chain reaction 
The optimal reaction mixture (25 µl) for APC's exon 11 amplification was: 10 pmol of 
each primer (5'-GGACTACAGGCCATTGCAGAA-3' and 5'-
GGCTACATCTCCAAAAGTCAA-3'), 200-400 ng template DNA, 2.5 µ
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buffer II (500 mM KCl, 100 mM Tris-HCl, pH 8.3), 1 mM MgCl2, 2.5 mM of each dNTP, 1 
µl (0.5 U) of Taq polymerase. Polymerase chain reaction (PCR) conditions were: initial 
denaturation, 4 min/95°C; denaturation, 1 min/94°C; annealing, 2 min/58°C; extension, 1.5 
min/72°C; 35 cycles. To amplify fragment of the exon 15 of the APC gene we used in a 
volume of 25 µl: 5 pmol of each primer (5-ATGATGTTGACCTTTCCAGGG-3 and 5-
CTTTTTTGGCATTGCGGAGCT-3), 200 ng template DNA, 2.5 µl 10X buffer II, 1.5 mM 
MgCl2, 2.5 mM of each dNTP, 1 µl (5 U) of Taq polymerase. PCR conditions were: initial 
denaturation, 5 min/95°C; denaturation, 30 s/95°C; annealing, 30 s/57°C; extension, 45 
s/72°C; final extension, 72°C/7 min; 30 cycles. The PCR products for both markers were 
analyzed on 2% agarose gels. 
Loss of heterozygosity 
Loss of heterozygosity of the APC gene was detected on the basis of restriction 
fragment length polymorphism (RFLP) of the PCR products. Two different polymorphisms 
were investigated. One is an Rsa I polymorphic site in exon 11, and the other is an Msp I 
polymorphic site in exon 15. PCR amplification of exon 11 generated a 133- bp fragment that 
is cleaved to 85- and 48- bp fragments by Rsa I restriction if the polymorphic site is present, 
and remains uncleaved if the site is absent. The amplified fragment of exon 15 is 550 bp long 
and is cleaved with the Msp I restriction endonuclease to two 250 bp fragments if the 
restriction site is present. LOH/Rsa I was demonstrated only in informative (heterozygous) 
persons when the tumor DNA showed loss of either the single uncut band (133 bp) or of the 
two cut bands (85+48 bp) compared to autologous blood tissue. For Msp I polymorphism 
heterozygous patients demonstrated two bands (550+250 bp), while LOH was shown when 
either band was missing in comparison to the autologous blood tissue. PCR aliquots (10-15 
µl) were digested with 6 U Rsa I (Gibco, USA; 12 h at 37°C) and with 6 U Msp I (Gibco, 
USA, overnight at 37°C) and were electrophoresed on Spreadex gels EL 300 in the SEA 2000 
submarine electrophoresis apparatus (Elchrom scientific, Switzerland) at 120V. Temperature 
of the running buffer was kept constant at 55°C. The samples with LOHs were additionally 
electrophoresed on 15% polyacrylamide gels stained with silver.  
Immunohistochemistry 
Immunohistochemistry was performed in order to establish the levels of expression 
and cellular localization of APC and beta-catenin proteins. The samples were formalin-fixed, 
paraffin embedded, and 4-mm thick sections were placed on Capillary gap microscope slides 
(DakoCytomation, Denmark). The sections were immunostained using the biotin–avidin–
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horseradish peroxidase method. Deparaffinized and rehydrated sections were microwaved in 
Dako Target Retrieval Solution (Dako Corporation, USA) three times for 5 min at 800 W to 
unmask epitopes. To block endogenous peroxidase activity, we fixed the cells in methanol 
containing 3% H2O2. Non-specific binding was blocked by the application of normal mouse 
serum for 30 min in a humid chamber. Slides were blotted and primary antibodies at 
optimized dilutions were applied for 30 min at room temperature. The antibodies used for 
APC protein detection were: APC-1 monoclonal mouse anti-human antibody that recognizes 
amino terminal epitope (diluted 1:50) (Calbiochem, USA) and APC-2 monoclonal rabbit anti-
human antibody (ready-to-use) that recognizes carboxy terminal epitope (Spring Bioscience, 
USA). Monoclonals used for β-catenin detection were: monoclonal mouse anti-human 
antibody (diluted 1:200) from Dako Corporation, USA.  
After incubation, the slides were washed three times in phosphate-buffered saline/goat 
serum. Secondary LINK antibody was applied for 25 min. The washing was repeated, and the 
slides were incubated with streptavidin horseradish peroxidase for another 25 min. All 
chemicals were from DakoCytomation. Negative controls were samples that underwent same 
staining procedure with the exclusion of the primary antibodies. Normal skin served as 
positive internal control. The analysis of the labeling was performed by two independent 
observers, i.e. blinded pathologists, experts in the field on an Olympus BH-2 microscope. 
Statistical methods 
All individuals were analyzed for the following features: PHD status, sex, age, APC 
LOH, APC and beta-catenin protein expression. Differences in the frequencies of the 
analyzed features were tested with the χ2 test employing Yates correction when appropriate.  
 
Results 
The pathohistological grading of the meningioma sample analyzed is shown in Table 
1.  
From 33 meningioma samples 32 were informative when analyzed with both APC 
gene markers (97%). The results of our analysis regarding APC gene, demonstrated 15 
samples with allelic losses of the APC gene out of 32 heterozygous patients (47%). This is the 
total number of changes analyzed by both polymorphic markers, RsaI/exon 11 and MspI/exon 
15. When specifying changes to distinct gene regions, there were 11 alterations in exon 11 
(39%) and 11 in exon 15 (39%). Seven meningioma samples showed both LOHs at exon 11 
and 15, while 4 LOHs were exclusive for exon 11 and 4 for exon 15.  LOHs of the APC gene 
that both markers revealed are shown in Figure 1 A (exon 11) and B (exon 15).  
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When distributing APC’s changes to specific tumor types, we observed 6 allelic 
changes in 13 informative meningothelial meningiomas (46%); 2 in 6 informative fibrous 
(33%); 3 in 4 informative transitional (mixed) (75%); 3 in 4 informative angiomatous (75%); 
and 1 LOH in a single case of psammomatous meningioma.  
Two atypical and two anaplastic meningiomas that we examined did not demonstrate 
allelic changes of APC gene tested with both markers.  
In order to determine whether APC changes at the genetic level have consequences in 
meningiomas at the protein level, the expression of APC protein was investigated. We 
employed the combination of two different monoclonal APC antibodies, not only to analyze 
the levels of expression, but to detect truncated mutant proteins as well. Since Ab-1 
recognizes the amino terminus of the protein and hence reacts with both the wild-type and 
mutant proteins, we were able to demonstrate lack of protein expression in 39% of our total 
sample. Lack of staining was confirmed with Ab-2 antibody that recognizes the carboxy 
terminus and reacts only with the nontruncated wild-type proteins. Only those samples 
positive for APC’s expression with Ab-1, but negative when tested with Ab-2, revealed 
mutant proteins, lacking carboxy terminus. Mutant proteins were detected in 27% of our total 
sample. Ten out of 15 meningioma samples with APC LOH, did not express wild type APC 
protein (66.7%), while in the remaining 5 samples with LOH, mutant APC protein was 
detected. The findings on the protein levels and types are shown in Table 1.  
The association between APC genetic changes and lack of protein expression or 
presence of mutant proteins was significant (χ2 =13.81, df = 2, P<0.001) as shown in Table 2. 
Our next step was to detect whether the expression and cellular localization of the 
main downstream signaling effector molecule, beta-catenin, correlated with LOH of APC 
gene. Our findings demonstrated that there is significant association (χ2 =21,96, df = 2, 
P<0.0001) between the LOHs of APC and the localization of beta-catenin protein (Table 3). 
In all cases where LOH was noted beta-catenin protein was located in cytoplasm and nucleus. 
At the same time in cases where APC’s LOH was not detected the location of the beta-catenin 
protein was primarily in the membrane or was not detectable (Table 3). Immunostaining of 
APC and beta-catenin proteins is demonstrated in Figure 2. 
When we correlated our molecular findings with the demographic variables we were 
unable to demonstrate that LOH was significantly associated with the analyzed age categories, 
although at the descriptive level, 11/15 LOHs were noted in patients over 56 years of age. The 
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correlation of observed LOHs to invasion was as follows: two meningiomas with LOHs 
infiltrated dura, one had bone invasion and another one was a case of recurring meningioma.  
Due to a small number of cases in certain meningioma subtypes, the correlation of 
APC genetic changes to specific PHD status was not significant. Nevertheless, at the 
descriptive level LOH frequencies are higher in mixed and angiomatous histology (7/9, 
77.8%) than in meningothelial and fibrous (8/19, 42%). Aggressive forms did not show 
changes. Genomic changes, the polymorphic status for both markers used, and protein 
expression are summarized in Table 1.  
 We also tested our meningioma sample to NF-2 genetic changes. We observed two 
LOHs by microsatellite marker D22S929 (in sample no. 4 and sample no. 14, Table 1), but 
those findings could not be correlated to the results with APC.  
 
Discussion 
Identification of new genes that will improve the understanding of meningioma 
development and eventual progression is very important. 
The majority of meningiomas we analyzed were slow-growing, benign sporadic 
lesions with seemingly low metastatic potential. However, biologic spectrum of meningiomas 
is wide, heterogenic and difficult to predict [20]. Some of the histologically benign 
meningiomas recur unexpectedly even after complete resection and invade surrounding 
tissues [20]. Novel revisions of meningioma classification [9] recommend caution on benign 
meningioma prognosis, proposing their proliferative activity and brain invasion as important 
characteristics that could indicate recurrence and should be considered in diagnostics and 
prognosis.  
The result of this study demonstrates that changes of APC gene are frequent among 
benign meningioma types (47%). The considerable number of allelic losses of the APC gene 
in our meningioma sample may be attributed to random variation in tumors, but the observed 
frequency led us to conclude that gross deletion of the APC gene are an important event in the 
mechanisms of meningioma formation. Moreover, the functional consequences of the changes 
were confirmed at the protein level. Our results on the significant association between APC 
genetic changes and lack of wild type protein expression or presence of mutant proteins (χ2 
=13.81, df = 2, P<0.001) indicate that gross deletions are consistent to the protein findings.  
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Association between LOHs of APC and nuclear location of beta-catenin protein (χ2 
=21,96, df = 2, P<0.0001) show that APC changes influence beta-catenin expression and 
localization, and are important in the biology of meningioma.  
 At the descriptive level we observed the distinction of the frequencies of LOH 
occurrences between meningothelial and fibrous on one side and mixed and angiomatous on 
the other. Mixed and angiomatous histology showed somewhat higher frequency of LOH of 
this gene. Changes of APC gene observed in specific meningiomas were also partially 
associated with their invasion into the surrounding tissues and recurrence. 
No LOHs were found in atypical and anaplastic cases, but since the numbers of cases 
investigated was rather small it was difficult to interpret this finding. 
The survey by Wrobel and co-workers [21] who observed that anaplastic meningiomas 
could be distinguished from benign by differential expression of a distinct set of genes, 
suggests that benign forms and those with greater likelihood of recurrence and aggressive 
behavior could be governed by different genetic profiles. 
Our observations are in accordance with the findings of other authors investigating 
different components (direct and indirect) of wnt signaling in meningiomas. For example E-
cadherin’s allelic losses were observed in fibrous and angiomatous meningiomas. Since the 
loss of E-cadherin is a well known prerequisite for tumor cell invasion [22], the finding 
suggests that those meningioma types may hide future invasive behavior. Schwechheimer and 
coworkers [23] found that E-cadherin’s expression was absent from the majority of 
morphologically malignant meningiomas and that the loss of its expression was correlated 
with tumor dedifferentiation. Utsuki et al. [24] also reported on negative E-cadherin 
immunostaining in all of the fibrous meningiomas they examined. Brunner et al. [25] found 
lack of E-cadherins expression in 34% of meningiomas independent of their WHO grade as 
well as loss of membranous and positive nuclear immunoreactivity of beta-catenin. Wrobel 
and coworkers [21] reported on increased expression of beta-catenin and cyclin D1 in 
meningiomas they examined by microarray. Unfortunately they did not study APC expression 
profile.  
The discrepancies between our results and those obtained by Lee et al. [26] who failed 
to detect an enhanced occurrence of LOH of the APC gene in meningiomas they examined, 
may be explained by several factors. Firstly, Lee and co-workers used 2 microsatellite 
markers that map to cytogenetic band 5q23.3 which is in proximity to APC/MCC region, 
while we used intragenetic markers (exon 15 and 11 of the APC gene). Genetic regions 
investigated in the two studies are not the same and therefore the ratios of LOHs may also 
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differ. Secondly, both studies analyzed relatively low number of cases for statistical 
interpretation. Nevertheless, Lee et al. found 1 LOH in 25 benign; and 3 LOHs in 9 atypical 
and malignant meningiomas, indicating that this genetic change is present in this disease.  
The observed genetic changes of the APC gene were dispersed among different types 
of meningioma, indicating once again that APC is not likely to be the first event in the raise of 
this specific tumor. Mutation and or loss of NF2 gene were found in meningiomas of all 
malignancy grades which make NF2 gene a candidate gatekeeper gene of meningioma 
initiation, i.e. first genetic change in its pathogenesis [10]. Although we were unable to 
establish correlation of NF-2 genetic changes to the results with APC, it seems that changes of 
APC gene are introduced later on in genetic profile of meningioma.  
We are aware that due to a small number of tumors in some of our grade subsets, 
conclusions should be made with caution. Nevertheless, our findings contribute to better 
understanding of meningioma genetic profile elucidating pathophysiological mechanisms of 
tumor formation, and could offer new prognostic markers for meningioma. 
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Figure 1. A. Loss of heterozygosity of APC gene in 3 patients with meningioma. Exon 
11/RsaI/RFLP is demonstrated. Lane 1- standard DNA; lanes 2, 3- heterozygous sample 
(tumor and blood); lane 4, 5- uninformative homozygous sample showing uncut allele (tumor 
and blood); lane 6 - LOH in a meningioma patient (the digested/cut allele is missing); lane 7- 
informative blood sample of the same patient showing undigested/uncut allele 133 bp and cut 
allele (85+48 bp); lanes 8, 10 - informative blood samples; lanes 9, 11 - LOHs in the 
corresponding meningioma samples.  
B. Loss of heterozygosity of APC gene in meningeoma patients. Exon 15/MspI/RFLP is 
demonstrated. Lanes 1, 6, 7, 10 - heterozygous samples, both alleles, cut and uncut, are 
visible; lanes 2, 4, 8, 12, 14, 15 – informative blood samples; lanes 3, 5, 9, 11, 13, 16 - LOHs 






Figure 2. Meningioma samples immunohistochemically stained for the expression of APC 
and beta-catenin proteins. a. Patient with APC LOH negative for the expression of wild type 
APC protein (Ab-1 that recognizes the amino terminus was used). b. Patient without LOH 
positive to the expression of wild type APC protein (Ab-2 that recognizes the carboxy 
terminus was used). c. Patient with APC LOH demonstrating mutant APC protein (Ab-1 that 
recognizes the amino terminus was used). d. In same patient when tested with Ab-2, no 
staining was detected. e. Patient with APC LOH demonstrating nuclear and cytoplasmic 
localization of beta-catenin protein. f. Patient without APC LOH demonstrating membranous 




Table 1. Pathohistological grade, demographic variables,  the polymorphic status for markers 




















1 Meningothelial M 72 HETERO HETERO 
- - 
2 Meningothelial M 68 HETERO HETERO 
- 
M(+) 
3 Meningothelial F 70 HETERO HETERO WT(++) M(+) 
4 Meningothelial F 62 HETERO HETERO WT(++) M(+) 
5   MeningothelialDur M 64 LOH HETERO 
- 
CN(+) 
6 Meningothelial M 65 HETERO HETERO 
- 
CN(+++) 
7 Meningothelial M 35 HETERO HETERO WT(+) M(+) 
8 Meningothelial F 55 HETERO HETERO WT(++) MC(+) 
9 Meningothelial F 47 HOMO A HOMO 250 WT(+) 
- 
10   MeningothelialBon M 70 LOH HETERO MUTANT CN(+++) 
11    MeningothelialRec M 54 LOH LOH 
- 
C(++) 
12 Meningothelial F 69 LOH LOH 
- 
CN(+++) 
13 Meningothelial M 52 LOH HOMO 500 
- 
N(++) 
14 Meningothelial F 70 LOH LOH MUTANT N(+++) 
15 Fibrous 
(fibroblastic) 




F 63 LOH HOMO 250 MUTANT N(+) 
17 Fibrous 
(fibroblastic) 













F 73 HETERO HETERO MUTANT CN(+++) 
21 Transitional 
(mixed) 










M 45 HETERO HETERO WT(+) MC(+) 
24 Transitional 
(mixed)Dur 
F 50 LOH LOH 
- 
N(+++) 
25 Psammomatous F 60 HOMO A LOH MUTANT N(++) 
26 Angiomatous M 66 LOH LOH 
- 
CN(++) 
27 Angiomatous M 39 HETERO HETERO WT(++) 
- 
28 Angiomatous F 70 HETERO LOH 
- 
N(+) 
29 Angiomatous F 73 HOMO B LOH MUTANT CN(++) 
30 Atypical  M 76 HETERO HETERO WT(+) M(+) 
31 Atypical M 56 HOMO A HETERO WT(++) MC(++) 
32  Anaplastic 
(malignant) 
F 71 HETERO HOMO 500 WT(++) C(+) 
33 Anaplastic 
(malignant) 
F 69 HETERO HETERO WT(++) MC(+) 
LOH=loss of heterozygosity; HETERO =heterozygous samples; HOMO= homozygous samples; - = no 
expression; WT = wild type APC protein; MUTANT = truncated APC protein lacking carboxy terminus;  M = 





Table 2. Crosstabulation between presence of APC LOH and the expression of the APC 
protein. 
 
 APC protein 
 
No expression Expression wt Mutant protein 
Total 
         
APC O/N % O/N % O/N % O/N % 
         
No LOH 3/13 23.1 10/10 100.0 4/9 44.4 17/32 53.1 
LOH 10/13 76.9   5/9 55.6 15/32 46.9 
         
Total 13 100.0 10 100.0 9 100.0 32 100.0 
O = number of observed cases   
N = number of analyzed individuals 












Table 3. Crosstabulation between the presence of APC LOH and the expression and 





No expression Membraneous Cytoplasmic and 
nuclear 
Total 
         
APC O/N % O/N % O/N % O/N % 
         
No LOH 5/5 100.0 9/9 100.0 3/18 16.7 17/32 53.1 
LOH     15/18 83.3 15/32 46.9 
         
Total 5 100.0 9 100.0 18 100.0 32 100.0 
O = number of observed cases   
N = number of analyzed individuals 
 
 
 
 
 
